Array Comparative Genomic HybridizationMicroarray-based technology has provided a platform on which a large number of genomic aberrations can be assessed in a single experiment. CGI is focused on one application of the microarray technology, known as array comparative genomic hybridization or array-CGH, to detect DNA copy number changes (gain/loss) frequently observed in cancers. Targeted arrays in various stages of design and development include those for diagnostic and prognostic purposes in lymphomas, genitourinary cancers, gynecological cancers and leukemias.
UGenRA™ is a CGI custom-designed oligonucleotide array designed to detect gains and losses of genomic material in endometrial, ovarian, and cervical cancers. Endometrial hyperplasia is a precursor lesion of endometriod endometrial carcinoma (EEC) and since about 50% of women with atypical hyperplasia also have concurrent EEC, it is important to identify those precursor lesions more likely to progress to and those with frank cancer. UGenRA™ offers the opportunity to identify such specimens and potentially guide clinical management. Another potential application is to stratify those tumors likely to recur, permitting the identification of patients most likely to benefit from adjuvant therapy. Risk-stratification of stage III/IV ovarian cancer patients after cytoreductive surgery for front-line platinum taxane-based chemotherapy is a potential application for UGenRA™, and the design currently contains the sites of genomic gain/loss with such prognostic value. For any of the three cancers, genomic gain/loss associated with response to particular therapies can be assessed using UGenRA™, especially with the need of only small amounts of starting material and the ability to perform UGenRA™ on FFPE specimens.